Expression of the VEGF marker in endometrial cells in hyperplastic processes
DOI:
https://doi.org/10.12775/JEHS.2020.10.10.008Keywords
endometrial hyperplasia, atypical endometrial hyperplasia, angiogenesis, VEGF, malignancyAbstract
Hormone-dependent diseases related to preproliferative processes and endometrial cancer have a clear tendency to increase and rejuvenate. The purpose: to study the expression of VEGF marker in endometrial cells under physiological, hyperplastic, atypical conditions in women’s different age periods. 2196 pathomorphological findings of endometrial tissue samples in women with clinical manifestations requiring surgical treatment have been analyzed. VEGF expression was performed in endometrial tissue samples of 458 women of late reproductive, perimenopausal and postmenopausal age. Each age category is characterized by its morphofunctional features of the endometrial tissue. Results. The frequency of detection of hyperplastic processes, atypical hyperplasia and adenocarcinoma indicates that starting from the period after 40 y.o. the mechanisms of initiation and development of factors in the system of self-sufficiency in mitogenic stimuli, constant proliferation and insensitivity to antimytogenic signals", loss of “Hayflick’s limit”, reduced ability to apoptosis, propensity to immortalization take place. Conclusion: The expression of VEGF concentration in endometrial tissue as an inducer of angiogenesis is increased in hyperplastic processes. Significant growth is observed in the processes of atypical hyperplasia, especially in the postmenopausal period. Determination of VEGF concentration in endometrial proliferative processes can be a promising marker for diagnosing the risk of atypical conditions and their prognosis. Research in this direction is quite relevant.
References
Blokhin D.Yu. "Post-genomic view" on the problems of oncogenesis / Clinical oncohematology .- 2009.- T2.- No. 3.- P.277-283.
Gershtein E.S., Kushlinsky D.N., Tereshkina I.V. and other Growth factor of vascular endothelium and tumors of the female reproductive system. Part 2. Ovarian and endometrial cancer. / Fundamental Oncology. - 2015. - No. 2. - P.2-11.
Levakov S.A., Sheshukova N.A., Kedrova A.G. et al. Molecular biological profiles of endometrial hyperplasia and endometrial intrinsic epithelial neoplasia. / 2018.- T.14.- No. 2.- P.76-81.
Orazov M.R. Discussion issues of management of patients with endometrial hyperplasia. / Akusherst. I Ginek. News, opinions, training.- 2015.- No. 3.- P. 46-58
Chernukha G.E., Asaturova A.V., Ivanov I.A. et al. The structure of endometrial pathology in different age periods / Akush. iginek.- 2018.- No. 8.- P.129-134.
Chumak ZV, Zelinsky AA, Shapoval NV Immunohistochemical and molecular genetic markers of hyperplastic and unoplastic endometrium.- Bulletin of morphology.- 2015.- No. 2 (T.21) .- P.547- 552.
Anna M. Mahecha, Hongbo Wang. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and-9 in angiogenesis, metastasis, and prognosis of endometrial cancer.-Onco Targets Ther.- 2017.- 10, 4617-4624.
Chumak Z.V., Shapoval M.V., Artyomenko V.V. Age-related relationship between the development of hyperplastic processes and VEGF expression in endometrial cells. Journal of Education, Health and Sport. 2020;10(4):209-217. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.04.023
Enhanced expression of vascular endothelial growth factor and increased microvascular density in women with endometrial hyperplasia: a possible relationship with uterine natural killer cells. Elfayomy A.K., Almasry S.M., Attia G.M. et al. // Rom J MorpholEmbryol.- 2015;56(2 Suppl):725-34.
Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Wang J., Taylor A., Showeil R. et al. // Cytokine.- 2014.- Aug; 68(2): 94-100.
Xu N., Sun X., Sun W-J. Expresion and clinical correlation of NGAL and VEGF in endometrial carcinoma.-Eur Rev Med Pharmacoi Sci. 2018. Feb. - 22 (3), 632-636.
Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Wang J., Taylor A., Showeil R. et al. // Cytokine.- 2014.- Aug; 68(2): 94-100.
Vascular endothelial growth factor (VEGF) regulation by hypoxia inducible factor-1 alpha (HIF1A) starts and peaks during endometrial breakdown, not repair, in a mouse menstrual-like model. Xihua Chen, Jianbing Liu, Bin He et al. // Human Reproduction June 2015.- 30(9).-DOI: 10.1093/humrep/dev156
New concepts for an old problem: the diagnosis of endometrial hyperplasia. Peter A. Sanderson, Hilary O.D. Critchley, Alistair R.W. Williams.// Hum Reprod Update.-2017.- Mar.23 (2).- P.232-254
James V. Lacey Jr., Victoria M. Chia. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas.- 63.-2009.-P.39–44.
Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia.Monica Hagan Vetter, Blair Smith, Jason Benedict et al. Original Research Gynecology.- 2020.-V.222. Yan/ 01.-P.60/ https://doi.org/10.1016/j.ajog.2019.08.002
ShivajiNeelgund, P. B. Hiremath. Abnormal uterine bleeding in perimenopause.// Gale academic onefile.- June 27, 2016. P.375-381.
The significance of sonographically thickened endometrium in asymptomatic postmenopausal women. Runa Ozelci, Berna Dilbaz, Funda Akpınar et al.// Obstet Gynecol Sci. 2019;62(4):273-279. Published online June 24, 2019.- DOI: https://doi.org/10.5468/ogs.2019.62.4.273
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 541
Number of citations: 0